After receiving his Ph.D. in Biochemistry and Molecular Biology at the University of Zürich, Switzerland, Prof. Linden trained in Molecular Virology at Cornell University Medical College, N.Y. After his postdoctoral training he joined the faculty at Mount Sinai School of Medicine in New York, where he used a multidisciplinary approach to understanding the molecular mechanisms and the potential applicability of site-specific genome integration by adeno-associated virus (AAV). In 2007, he moved continents to set up a new research group at King’s College London as the chair in Molecular Virology.
His contributions to the field include the biochemical and structural determination of the AAV Rep proteins, which orchestrate all aspects of the AAV life cycle, and the proposal of a mechanism of site-specific integration. During these studies Prof. Linden’s laboratory has demonstrated the potential of using embryonic stem cells for gaining insights into complex viral mechanisms.
Throughout his career, Prof. Linden has engaged in the field of AAV-mediated gene therapy including a role as the Director of the UCL Gene Therapy Consortium where he was responsible for clinical grade vector production and the support for further developments in UK based gene therapy efforts. In this context Prof. Linden was actively engaged in translational projects aimed at the development of novel therapies using AAV-based vectors.
In December 2014 Prof. Linden joined Pfizer Inc as the Vice President of Gene Therapy, to establish and lead the Genetic Medicine Institute in London. He has held this position until August 2017.